Dasatinib for treatment of CAR T-cell therapy-related complications
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/12/e005956.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162750846664704 |
|---|---|
| author | Jakob R Passweg Dominik Heim Katharina Baur Astrid Beerlage Anna S Poerings Bastian Kopp Michael Medinger Jan C Dirks Andreas Holbro |
| author_facet | Jakob R Passweg Dominik Heim Katharina Baur Astrid Beerlage Anna S Poerings Bastian Kopp Michael Medinger Jan C Dirks Andreas Holbro |
| author_sort | Jakob R Passweg |
| collection | DOAJ |
| description | Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies. |
| format | Article |
| id | doaj-art-06820fb0139b4c2d934df387af8e13dd |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-06820fb0139b4c2d934df387af8e13dd2025-08-20T02:22:28ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-12-01101210.1136/jitc-2022-005956Dasatinib for treatment of CAR T-cell therapy-related complicationsJakob R Passweg0Dominik Heim1Katharina Baur2Astrid Beerlage3Anna S Poerings4Bastian Kopp5Michael Medinger6Jan C Dirks7Andreas Holbro81 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, Switzerland1 Division of Hematology, University Hospital, Basel, SwitzerlandCytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies.https://jitc.bmj.com/content/10/12/e005956.full |
| spellingShingle | Jakob R Passweg Dominik Heim Katharina Baur Astrid Beerlage Anna S Poerings Bastian Kopp Michael Medinger Jan C Dirks Andreas Holbro Dasatinib for treatment of CAR T-cell therapy-related complications Journal for ImmunoTherapy of Cancer |
| title | Dasatinib for treatment of CAR T-cell therapy-related complications |
| title_full | Dasatinib for treatment of CAR T-cell therapy-related complications |
| title_fullStr | Dasatinib for treatment of CAR T-cell therapy-related complications |
| title_full_unstemmed | Dasatinib for treatment of CAR T-cell therapy-related complications |
| title_short | Dasatinib for treatment of CAR T-cell therapy-related complications |
| title_sort | dasatinib for treatment of car t cell therapy related complications |
| url | https://jitc.bmj.com/content/10/12/e005956.full |
| work_keys_str_mv | AT jakobrpassweg dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT dominikheim dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT katharinabaur dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT astridbeerlage dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT annaspoerings dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT bastiankopp dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT michaelmedinger dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT jancdirks dasatinibfortreatmentofcartcelltherapyrelatedcomplications AT andreasholbro dasatinibfortreatmentofcartcelltherapyrelatedcomplications |